Completed pre-IND meeting following MGX-001 preclinical data demonstrating curative FVIII activity in non-human primates (NHPs) and remains on track for global regulatory submission including investig ...

Methods developed and validated to establish the "World Bank of NK Cells" from healthy donors and cancer patients -- Single apheresis yields up to 5 billion (5×109) highly pure activated memory ...

The St. Elizabeth Lady Hornets, at long last, have arrived to the biggest stage of the girls basketball season, playing their ...

Bitmine crypto holding reigns as the #1 Ethereum treasury and #2 global treasury, behind Strategy Inc. (NASDAQ: MSTR), which ...

Maryville, Tennessee-- (Newsfile Corp. - March 5, 2026) - Smith & Wesson Brands, Inc. (NASDAQ: SWBI), a U.S.-based leader in firearm manufacturing and design, today announced financial results for the ...

RAP-219's lead program demonstrated robust and consistent activity in patients with focal onset seizures (FOS) in Phase 2a trial; initiation of Phase 3 program expected in the second quarter of 2026RA ...

On Friday, Braemar Hotels & Resorts (NYSE: BHR) discussed fourth-quarter financial results during its earnings call. The full ...

Highlights Revenues of $263.5 million for the quarter ended January 25, 2026; operating earnings of $8.2 million; and net loss from continuing operations of $0.2 million (0.00 $ per share).Adjusted op ...

Tractor Supply Co. grand opening, all day, 1604 Highway 33 S., Cloquet. Giveaways and 10% off purchase. Bingo, 1 p.m., Grand View Grill and Bar, 2820 Midway Ave., west of Duluth. $25 for one ...

CANOPY reports twelve strategies for creating a sustainable, future-proof office by 2026, focusing on effective design, location, and technology.

Nomura Tax-Free USA Fund Institutional Class shares underperformed the Fund's benchmark by 87 bps, returning 0.69% vs. 1.56% for its benchmark, the Bloomberg Municipal Bond Index, for 4Q25.

Data readout for SIM0505/CDH6 ADC Phase 1 dose escalation study and initiation of dose optimization in ovarian cancer are both anticipated in Q2 2026LNCB74 Phase 1 dose escalation trial update planned ...